

type of report	Current report
number	7/2013
date of publication	2013-02-11 15:44:01
company	PHARMENA

#### **Entering into agreement on 1-MNA dietary supplement formulation development**

With reference to the Company's Strategy for 2012-2015 (published in current report no. 16/2012 of 13<sup>th</sup> April 2012), the Management Board of Pharmena S.A. informs that on 11<sup>th</sup> February 2013 it entered into agreement on 1-MNA dietary supplement formulation development with Master Pharm Polska Sp. z o.o. Having developed the formulation and registered the 1-MNA dietary supplement as new foodstuff within the European procedure, the company will place the product on the EU markets.

Dietary supplement 1-MNA is an innovative product with a capacity to influence the risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin which reduces the risk of atherosclerosis development.

Master Pharm Polska Sp. z o.o. is a Polish leader in developing and contract manufacturing of dietary supplements, foods for particular nutritional uses, cosmetics, medical products.

The information is made public due to the fact that introduction of innovative dietary supplement containing 1-MNA on the market may have a significant influence on the Company's revenue in the next few years.

Legal basis: Alternative Trading System Rules – Exhibit 3 “Current and Periodical Information in the Alternative Trading System on the NewConnect Market”, Article 3 (1).

#### **Representatives of the company:**

- Konrad Palka - President of the Board
- Marzena Wieczorkowska – Vice President of the Board